Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis (CNS Drugs, (2022), 36, 6, (569-589), 10.1007/s40263-022-00920-6)

Research output: Other contributionResearch

View graph of relations

This article was made available online at https://link.springer.com/article/10.1007/s40263-022-00920-6 on 19 May 2022. An error was subsequently identified in the article, and the following correction should be noted: Page 14, column 1, section 7.3, paragraph 1, lines 1-4: The following sentences, which previously read: “Ofatumumab is a fully human anti-CD20 monoclonal antibody and the B-cell-depleting drug most recently approved for the treatment of RRMS. It is administered subcutaneously at a dose of 30 mg every 4 weeks.” Should read: “Ofatumumab is a fully human anti-CD20 monoclonal antibody and the B-cell-depleting drug most recently approved for the treatment of RRMS. It is administered subcutaneously at a dose of 20 mg every 4 weeks.” The original article has been corrected.

Original languageEnglish
Publication dateAug 2022
Edition8
Volume36
Number of pages1
DOIs
Publication statusPublished - Aug 2022
SeriesCNS Drugs
ISSN1172-7047
NullPointerException

ID: 79703908